SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin

Article Cardiac & Cardiovascular Systems

Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease

Tamique Mason et al.

Summary: The study shows that empagliflozin treatment for 6 months can reduce ECV, iECV, and LVMi in individuals with T2DM and CAD, with no impact on MMP-2 and sST2. Further research on the mechanisms of empagliflozin-induced reverse remodeling is needed.

JACC-CARDIOVASCULAR IMAGING (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis

Richard K. Cheng et al.

Summary: This study found no association between the use of neurohormonal blockade and survival in patients with transthyretin cardiac amyloidosis. Discontinuing beta-blockers may be associated with improved survival in the overall cohort.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial

Jawad H. Butt et al.

Summary: Dapagliflozin was equally effective and safe in reducing the risk of worsening heart failure events in both men and women with HFrEF. It also improved symptoms, physical function, and health-related quality of life compared to placebo.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Jr James L. Januzzi et al.

Summary: This study found that empagliflozin treatment reduced the risk of heart failure or renal events regardless of baseline NT-proBNP concentration in patients with heart failure.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

NT-proBNP Response to Heart Failure Therapies An Imperfect Surrogate

Jonathan W. Cunningham et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems